> Details

Vicentino, Amanda Roberta Revoredo; Fraga‐Junior, Vanderlei da Silva; Palazzo, Matheus; Tasmo, Natalia Recardo Amorim; Rodrigues, Danielle A. S.; Barroso, Shana Priscila Coutinho; Ferreira, Sâmila Natiane; Neves‐Borges, Anna Cristina; Allonso, Diego; Fantappié, Marcelo Rosado; Scharfstein, Julio; Oliveira, Ana Carolina; Vianna‐Jorge, Rosane; Vale, André Macedo; Coutinho‐Silva, Robson; Savio, Luiz Eduardo Baggio; Canetti, Claudio; Benjamim, Claudia Farias

High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID‐19 patients: HMGB1 as a biomarker of worst prognosis

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID‐19 patients: HMGB1 as a biomarker of worst prognosis
  • Contributor: Vicentino, Amanda Roberta Revoredo; Fraga‐Junior, Vanderlei da Silva; Palazzo, Matheus; Tasmo, Natalia Recardo Amorim; Rodrigues, Danielle A. S.; Barroso, Shana Priscila Coutinho; Ferreira, Sâmila Natiane; Neves‐Borges, Anna Cristina; Allonso, Diego; Fantappié, Marcelo Rosado; Scharfstein, Julio; Oliveira, Ana Carolina; Vianna‐Jorge, Rosane; Vale, André Macedo; Coutinho‐Silva, Robson; Savio, Luiz Eduardo Baggio; Canetti, Claudio; Benjamim, Claudia Farias
  • Published: Wiley, 2023
  • Published in: Clinical and Translational Science, 16 (2023) 4, Seite 631-646
  • Language: English
  • DOI: 10.1111/cts.13475
  • ISSN: 1752-8054; 1752-8062
  • Origination:
  • Footnote:
  • Description: AbstractThe severe acute respiratory syndrome coronavirus 2, the agent of the ongoing coronavirus disease 2019 (COVID‐19) pandemic, has spread worldwide since it was first identified in November 2019 in Wuhan, China. Since then, progress in pathogenesis linked severity of this systemic disease to the hyperactivation of network of cytokine‐driven pro‐inflammatory cascades. Here, we aimed to identify molecular biomarkers of disease severity by measuring the serum levels of inflammatory mediators in a Brazilian cohort of patients with COVID‐19 and healthy controls (HCs). Critically ill patients in the intensive care unit were defined as such by dependence on oxygen supplementation (93% intubated and 7% face mask), and computed tomography profiles showing ground‐glass opacity pneumonia associated to and high levels of D‐dimer. Our panel of mediators included HMGB1, ATP, tissue factor, PGE2, LTB4, and cys‐LTs. Follow‐up studies showed increased serum levels of every inflammatory mediator in patients with COVID‐19 as compared to HCs. Originally acting as a transcription factor, HMGB1 acquires pro‐inflammatory functions following secretion by activated leukocytes or necrotic tissues. Serum levels of HMGB1 were positively correlated with cys‐LTs, D‐dimer, aspartate aminotransferase, and alanine aminotransferase. Notably, the levels of the classical alarmin HMGB1 were higher in deceased patients, allowing their discrimination from patients that had been discharged at the early pulmonary and hyperinflammatory phase of COVID‐19. In particular, we verified that HMGB1 levels above 125.4 ng/ml is the cutoff that distinguishes patients that are at higher risk of death. In conclusion, we propose the use of serum levels of HMGB1 as a biomarker of severe prognosis of COVID‐19.
  • Access State: Open Access